IMPART
IMPART is a non-profit virtual research institute at Dalhousie Medicine New Brunswick that conducts collaborative cardiovascular and metabolic research and operates a CTRnet-certified cardiac biobank serving academic and clinical partners across Canada.
- Company typePrivate
- Founded-
- HeadquartersSaint John, Canada
- Headcount1–10
- GTM typeB2B
- OfferingServices
What IMPART does
IMPART is a national virtual research institute headquartered at Dalhousie Medicine New Brunswick in Saint John, New Brunswick. Founded in 2017 by Dr. Keith Brunt with Dr. Jean-François Légaré, it operates as a collaborative research network — not a standalone commercial entity — and reports an internal team of 5 supported by a broader affiliated network of 45 academic and clinical partners across 8 universities and 6 Canadian provinces, 25 community and funding-agency members, 15 private-sector representatives, and two provincial government departments.
The institute's research is structured around three pillars: Inflammation and Metabolism, Physical Ability, and Research Translation, with a primary focus on cardiovascular health, metabolism, and chronic disease (diabetes, obesity, COPD, frailty, and select cancers). Core technical assets include the CTRnet-certified IMPART Biobank of annotated human cardiac tissue and blood specimens located at Dalhousie Faculty of Medicine adjacent to Saint John Regional Hospital; the MyROaD training program offering multi-institutional lab exchanges and industry micro-credentials; the Vulnerability Index mobile app that scores patient vulnerability across eight social determinants of health; the IMPART Podcast; and CardioTalk, a cardiovascular research seminar series. Underlying laboratory capabilities span gene and protein therapy, biologics, nanopharmacology, immunotherapeutics, stem-cell therapy, biomaterials, and regenerative medicine.
IMPART is funded almost exclusively by Canadian public and charitable research grants (NSERC, CIHR, Heart and Stroke Foundation, Canadian Diabetes Association, New Brunswick Health Research Foundation, Dalhousie Medicine). It has no commercial pricing model, sells no products, and conducts no sales-led go-to-market; dissemination occurs through academic publications, the Vulnerability Index app, clinical practice adoption via the New Brunswick Heart Centre partnership, and technology commercialization via industry collaborators such as Cloud DX and NB-BioMatrix.
IMPART firmographics
Firmographics- Name
- IMPART
- Legal name
- Dalhousie Medicine New Brunswick
- Website
- https://impart.team
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- IMPART is a non-profit virtual research institute at Dalhousie Medicine New Brunswick that conducts collaborative cardiovascular and metabolic research and operates a CTRnet-certified cardiac biobank serving academic and clinical partners across Canada.
- Ownership category
- akta.pro rank
IMPART industry classification
Industry- Product category
- Medical Research (Cardiovascular and Metabolism)
- NAICS
- Other Scientific and Technical Consulting Services (54169), Educational Support Services (61171)
- SIC
- Services-Misc Health & Allied Services, Nec (8090), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Imaging & Cardiac Safety Core Labs (ECOG/EEG/ECG) (HLAGAAAJ)
- akta.pro secondary industries
- Clinical Research Support (CRC/CTA) (EDAOAJAO), eCOA/ePRO/eDiary & Patient-Facing Data Collection (HLACAOAB)
Keywords
Where IMPART is headquartered
LocationHeadquarters
- HQ city
- Saint John
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
IMPART business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
Revenue model
- Research Grants and Funding: IMPART is supported by government research funding agencies including Natural Sciences and Engineering Research Council (NSERC), Canadian Institutes of Health Research (CIHR), and Dalhousie Medicine. The institute conducts collaborative research funded by various national and provincial research foundations.
- Research Grants: Individual researchers receive grants from organizations such as Canadian Diabetes Association ($300,000 over 3 years for Dr. Pulinilkunnil), Heart and Stroke Foundation, New Brunswick Health Research Foundation, and other medical research foundations.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
IMPART product offering
Product offeringCore offering
IMPART is a national virtual research institute that conducts fundamental, clinical, and translational research in cardiovascular health, metabolism, and chronic disease, organized around three core pillars: Inflammation & Metabolism, Physical Ability, and Research Translation. It operates the CTRnet-certified IMPART Biobank for human cardiac tissue samples, the MyROaD training program, the Vulnerability Index App for clinical vulnerability assessment, and supporting media properties (Podcast, CardioTalk, Research Reels). Research is delivered through a network of 45 academic and clinical partners across 8 universities and 6 Canadian provinces.
Product overview
IMPART is a national virtual research institute focused on fundamental, clinical, and translational research in inflammation, metabolism, physical ability, and research translation. The organization operates as a research collaboration rather than a commercial product company, offering research services including the IMPART Biobank for tissue sample storage, the MyROaD training program for researchers, a Vulnerability Index App for patient vulnerability assessment, the IMPART Podcast for patient stories, and CardioTalk for research presentations.
Differentiator
Problem solved
Functional benefit
Products and services
- IMPART Biobank A CTRnet-certified biorepository that collects, processes, and stores detailed annotated human heart samples, serum, plasma, and whole blood cells from volunteer participants undergoing cardiac surgery at the New Brunswick Heart Centre, with complete clinical data, serving cardiovascular researchers and the global scientific community.
- MyROaD Program (Maximize your Research on Obesity and Diabetes) A multi-institutional training program offering laboratory exchanges, EDI training, workshops on market commercialization, micro-credentialing, certification, internships among for-profit and non-profit industrial partners, and awards, designed for graduate and postdoctoral researchers in obesity and diabetes research.
- Vulnerability Index App A mobile application that helps physicians determine a patient's level of vulnerability using an algorithm based on eight social determinants of health (housing, income, food security, education and literacy, employment security, social support, personal health habits/coping skills, and family history) and connects patients with appropriate social agencies.
- IMPART Podcast A storytelling podcast featuring patient narratives and experiences navigating healthcare systems while living with diabetes, cardiovascular diseases, obesity, cancer, and other conditions, aimed at physicians, medical students, and healthcare professionals to initiate solution-oriented dialogue.
- CardioTalk A research presentation series through DalCREW that brings together local and international leaders in cardiovascular research for regular seminars, providing networking opportunities and a forum for trainees to present their research.
Quantifiable outcome
- Vulnerable populations (20% of NB population) represent 80% of healthcare costs ($2.75 billion budget)
- +2 more outcomes
Companies that use IMPART
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles2 records
IMPART technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
IMPART partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core, major and minor.
- Dalhousie Medicine New BrunswickcoreHost institution for IMPART located at Tucker Park campus in Saint John, NB. Provides infrastructure, faculty appointments, and administrative support for the research institute.
- New Brunswick Heart Centre (NBHC)coreSurgical center where biobank samples are collected from consenting cardiac surgery patients. Surgeons and physicians seek patient consent for tissue collection during procedures.
- Cardiovascular Research New Brunswick (CVRNB)majorCollaborating research organization that may request biobank samples and clinical data for cardiovascular research studies.
- Canadian Tumour Repository Network (CTRnet)coreNational network providing certification for the IMPART Biobank as a recognized biorepository meeting quality standards for tumour and tissue sample handling.
- NB-BioMatrix, Inc.majorDr. Keith Brunt serves as Chief Scientific Officer. Company focuses on health technology innovations and medical device development.
- University of New BrunswickmajorAcademic partner with faculty cross-appointments and collaborative research programs with IMPART investigators.
- University of GuelphmajorAcademic partner with special graduate faculty membership and collaborative research including Dr. Jeremy Simpson and Dr. Glen Pyle.
- Cloud DXminorHealth technology company whose Pulsewave wrist-worn blood pressure monitor was validated through IMPART-led clinical study at New Brunswick Heart Centre.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
IMPART competitors and assessment
Company assessmentPeers
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
IMPART social profiles
Digital presenceIMPART compliance and trust
Trust signalCompliance1 record
IMPART financial estimates
Financial estimateRevenue estimate
Valuation estimate
IMPART leadership team
Management profileNumber of profiles
Profiles6 records
IMPART funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
IMPART M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about IMPART
What does IMPART do?
IMPART is a national virtual research institute that conducts fundamental, clinical, and translational research in cardiovascular health, metabolism, and chronic disease, organized around three core pillars: Inflammation & Metabolism, Physical Ability, and Research Translation. It operates the CTRnet-certified IMPART Biobank for human cardiac tissue samples, the MyROaD training program, the Vulnerability Index App for clinical vulnerability assessment, and supporting media properties (Podcast, CardioTalk, Research Reels). Research is delivered through a network of 45 academic and clinical partners across 8 universities and 6 Canadian provinces.
Is IMPART a public or private company?
IMPART is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was IMPART founded?
IMPART was founded in -1. It employs 1 to 10 people.
Where is IMPART based?
IMPART is headquartered in Saint John, Canada, in the North America region.
How does IMPART make money?
Two revenue lines are on record. Research Grants and Funding is the primary driver. The others are research Grants.
Who are IMPART's main competitors?
Montreal Heart Institute (Institut de Cardiologie de Montréal) is listed as a peer.
Does IMPART have an API?
No public API is recorded for IMPART.
What industry is IMPART in?
IMPART's product category is Medical Research (Cardiovascular and Metabolism). Its primary akta.pro industry code is HLAGAAAJ, Imaging & Cardiac Safety Core Labs (ECOG/EEG/ECG), with a secondary code of EDAOAJAO, Clinical Research Support (CRC/CTA). Its NAICS code is 54169 and its SIC code is 8090.